Clover Health Investments, Corp.
NASDAQ:CLOVMedical - Healthcare Plans
+$0.17 today
- Market cap
- $2.21B
- Beta
- 2.48
- P/E (TTM)
- -45.6
- EPS (TTM)
- -$0.11
Volume 8.05M
Average 7.31M
CLOV Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Clover Health Investments, Corp.NASDAQ: CLOV
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow turns positive
Q2 FY2026 financing cash flow was $416K, compared with -$7.77M a year earlier. Trailing-twelve-month financing cash flow was -$21.33M. Over 3 fiscal years it compounded at +120.8% a year.
Context
- Financing cash flow amounted to 2.8% of revenue in FY2025, up 1.5 pp from a year earlier.
- Financing cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $416K or moves back toward the trailing-twelve-month quarterly average of -$5.33M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (53.38M) USD
- Year-over-year change
- -207.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (53.38M) | -207.5% |
| FY2024 | 2024-12-31 | (17.36M) | +48.7% |
| FY2023 | 2023-12-31 | (33.86M) | -582.4% |
| FY2022 | 2022-12-31 | (4.96M) | -100.5% |
| FY2021 | 2021-12-31 | 925.39M | — |
Financing Cash Flow vs competitors
How CLOV compares with its peers on the latest reported figures
- CLOV's LTM Jun 2026 financing cash flow of $21.33M is the 6th largest of the 7 companies compared; the peer median is $740.81M.
- Its year-over-year change of -57.6% is the 6th highest of 7, against a peer median of +88.5%.
- Financing cash flow amounts to 0.9% of revenue for CLOV, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $8.43B | +214.0% | -22.3% | 2.0% | |
| LTM Sep 2026 | $6.44B | +15.0% | -17.0% | 2.2% | |
| LTM Sep 2026 | $2.08B | +162.0% | -14.1% | 1.3% | |
| LTM Jun 2026 | $1.5B | -44.1% | -27.5% | 0.8% | |
| LTM Jun 2026 | $380.76M | +671.0% | +9.9% | 2.5% | |
| LTM Jun 2026 | $21.33M | -57.6% | +120.8% | 0.9% | |
| LTM Mar 2026 | $18.38M | -88.3% | +2.8% | 0.4% | |
| Peer median (excluding CLOV) | $740.81M | +88.5% | -15.5% | 1.7% | |
Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (587.76M) | (339.57M) | (213.36M) | (43.01M) | (85.55M) |
| Depreciation & Amortization | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M |
| Deferred Income Tax | (66.09M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 163.72M | 164.31M | 140.93M | 114.33M | 103.66M |
| Change in Working Capital | 192.67M | (2.36M) | (55.43M) | 12.86M | (84.2M) |
| Accounts Receivables | (9.39M) | (8.03M) | 0 | (6.55M) | (65.95M) |
| Inventory | 9.39M | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.31M | 7.64M | 4.74M | (2.62M) | 1.65M |
| Other Working Capital | 187.37M | (1.97M) | (60.17M) | 22.03M | (19.9M) |
| Other Non-Cash Items | 13.88M | (27.49M) | 9.48M | (50.66M) | (2.53M) |
| Operating Cash Flow | (282.33M) | (203.93M) | (115.87M) | 34.85M | (66.93M) |
| Capital Expenditures | (723K) | (4.47M) | (584K) | (1.56M) | (2.04M) |
| Acquisitions (Net) | 434.72M | (16.2M) | 0 | 0 | 0 |
| Purchases of Investments | (876.25M) | (369.65M) | (175.57M) | (201.24M) | (205.1M) |
| Sales of Investments | 441.53M | 485.45M | 316.16M | 203.36M | 211.22M |
| Other Investing Activities | (434.72M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (435.45M) | 95.13M | 140.01M | 565K | 4.08M |
| Debt Repayment | (30.93M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 289.92M | 1.4M | 1.15M | 902K | 1.81M |
| Common Stock Repurchased | (147K) | (6.36M) | (6.22M) | (18.26M) | (55.2M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 666.55M | 0 | (28.79M) | 0 | 0 |
| Financing Cash Flow | 925.39M | (4.96M) | (33.86M) | (17.36M) | (53.38M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 207.62M | (113.76M) | (9.72M) | 18.05M | (116.24M) |
| Free Cash Flow | (283.05M) | (208.39M) | (116.46M) | 33.29M | (68.98M) |
Clover Health Investments, Corp.
NASDAQ:CLOV
Intrinsic Alpha fair value
Locked
Current Price
$4.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.